CUE - CIK 0001645460
The table below shows Cue Biopharma, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$21.69M | -$36.33M | -$39.96M | -$41.81M | -$38.84M | -$32.49M |
| Capital expenditure | $177.00K | $66.00K | $0.00 | $171.00K | $913.04K | $595.26K |
| Investing cash flow | $75.00K | $32.00K | $25.00M | -$24.61M | $9.11M | $4.46M |
| Dividends paid | - | - | - | - | - |
Cue Biopharma, Inc. reported operating cash flow of -$21.69M for fiscal year 2025. That is up 40.3% from -$36.33M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$12.14M (FY 2017) to -$21.69M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | $0.00 | $200.00K | $750.13K | $271.05K |
| Financing cash flow | $26.29M | $10.24M | $11.86M | $53.66M | $19.23M | $58.61M |